NUMA1 and neoplasm: To improve diagnostic and follow-up strategies, urinary tumor biomarkers and other methods have been investigated, leading to the development of some FDA-approved tests, such as Bladder EpiCheck [41], Urovysion [42], nuclear matrix protein 22 (NMP22) [43], and bladder tumor antigen (BTA) [44].